Meet Cont®aFlu - a patent protected non-prescription remedy,
a safe and effective alternative to Tamiflu and Theraflu
Cont®aFlu is the first patent protected non-prescription product
for flu-like infections over the last 30+ years
The unique features of Cont®aFlu are:
It is based on Nobel Prize winning scientific discovery in innate immunity, that is has very solid scientific foundation and targets the mechanism of the disease
it is developed in full compliance with the principles of Evidence Based Medicine
it has the best possible IP protection: strong patents in the largest markets and a brilliant global trade mark
it is more effective for flu than any other product in this market niche
it can be positioned as the best option for people with chronic diseases, the population most vulnerable to flu complications and side effects of existing treatments
it can start off by winning patients' attention as a part of the family's first-aid kit for adults with chronic diseases
Cont®aFlu has all prerequisites to become the leader in over-the-counter (OTC) flu market niche thanks to its true novelty, efficacy, and an outstanding trade mark.
What's more, Cont®aFlu will also be able to compete with the best-selling OTC products owing to its therapeutic, regulatory and marketing profile.
Due to low manufacturing cost (<$0.70) Cont®aFlu can be affordable to patients in both high-income and middle-income countries.
Cont®aFlu is designed for health conscious people who prefer to treat flu with a safe and effective medication.
Cont®aFlu is destined to become a safe and effective, patent protected alternative to both Rx Tamiflu and OTC Theraflu-like products.
The IP package of Cont®aFlu is offered for acquisition to a company active in the OTC flu niche.
PRESS HERE to see the partnering proposal.
Project origin: EU (Belgium)
Press the button
to see the slide deck
Cont®aFlu is based on a groundbreaking discovery in innate immunity and an original drug development platform:
It makes use of a very promising molecular target; earlier attempts of large pharma companies to use it in viral infections has failed
Its author has prior experience of developing 6 other successful OTC products for Russian market
The key studies were performed in USA and Belgium
In influenza and flu-like infections Cont®aFlu provides:
Shorter disease duration by at least 2 days
Lower disease severity by at least 30%
Alleviation of major symptoms seen within 24 hours